Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Year: 2023
Type: supplementary-materials
Abstract: Supplementary methods, tables, figures 1-5 with corresponding figure legends, and references
Authors: Erika J. Lampert, Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon, Erin Nichols, Mohammad H. Bagheri, Elliott Levy, Marc R. Radke, Stanley Lipkowitz, Christina M. Annunziata, Janis M. Taube, Seth M. Steinberg, Jung-Min Lee
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362411053